{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "CHK1",
      "CIP2A",
      "DNA-PKc",
      "MYC",
      "P53",
      "PP2A",
      "biomarker",
      "drug resistance",
      "patient stratification",
      "personalized medicine",
      "prognostic role",
      "tumor grade"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "25628223",
  "DateCompleted": {
    "Year": "2016",
    "Month": "06",
    "Day": "01"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "12",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2015",
        "Month": "01",
        "Day": "28"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1002/ijc.29431"
    ],
    "Journal": {
      "ISSN": "1097-0215",
      "JournalIssue": {
        "Volume": "138",
        "Issue": "3",
        "PubDate": {
          "Year": "2016",
          "Month": "Feb",
          "Day": "01"
        }
      },
      "Title": "International journal of cancer",
      "ISOAbbreviation": "Int J Cancer"
    },
    "ArticleTitle": "Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers.",
    "Pagination": {
      "StartPage": "525",
      "EndPage": "532",
      "MedlinePgn": "525-32"
    },
    "Abstract": {
      "AbstractText": [
        "Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A), a recently identified oncogene, has emerged as a potential drug target for a range of different tumor types. High CIP2A expression has been reported in almost all solid organ cancers and in some hematological tumors and is associated with high grade and poor prognosis. Notably, high CIP2A expression is determined in over 70% of tumor patient samples in the majority of human cancers. High expression of CIP2A has also been proposed as a useful biomarker that predicts therapeutic response to chemotherapeutics such as Bortezomib, Erlotinib, Checkpoint Kinase 1 inhibitors and pro-senescence based therapies. In this review, we highlight, critically evaluate and discuss the ambiguity in CIP2A's prognostic role in different human cancers and its role in modulating response and resistance to chemotherapeutics."
      ],
      "CopyrightInformation": "\u00a9 2015 UICC."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Lowy Cancer Research Centre and Prince of Wales Clinical School, University of New South Wales (UNSW) Medicine Department, Sydney, New South Wales, 2052, Australia."
          }
        ],
        "LastName": "Khanna",
        "ForeName": "Anchit",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Lowy Cancer Research Centre and Prince of Wales Clinical School, University of New South Wales (UNSW) Medicine Department, Sydney, New South Wales, 2052, Australia."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Haematology, the Prince of Wales Hospital, Randwick, New South Wales, Australia."
          }
        ],
        "LastName": "Pimanda",
        "ForeName": "John E",
        "Initials": "JE"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Int J Cancer",
    "NlmUniqueID": "0042124",
    "ISSNLinking": "0020-7136"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Autoantigens"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Biomarkers, Tumor"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "CIP2A protein, human"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Intracellular Signaling Peptides and Proteins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Membrane Proteins"
    },
    {
      "RegistryNumber": "EC 2.7.-",
      "NameOfSubstance": "Protein Kinases"
    },
    {
      "RegistryNumber": "EC 2.7.11.1",
      "NameOfSubstance": "CHEK1 protein, human"
    },
    {
      "RegistryNumber": "EC 2.7.11.1",
      "NameOfSubstance": "Checkpoint Kinase 1"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "analysis",
        "physiology"
      ],
      "DescriptorName": "Autoantigens"
    },
    {
      "QualifierName": [
        "analysis"
      ],
      "DescriptorName": "Biomarkers, Tumor"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Checkpoint Kinase 1"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Genes, myc"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Intracellular Signaling Peptides and Proteins"
    },
    {
      "QualifierName": [
        "analysis",
        "physiology"
      ],
      "DescriptorName": "Membrane Proteins"
    },
    {
      "QualifierName": [
        "drug therapy",
        "pathology"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prognosis"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Protein Kinases"
    }
  ]
}